ESC 365 - No-reflow: prevention and pathophysiology - State of the art

ESC Premium Access

No-reflow: prevention and pathophysiology - State of the art

Session: No-reflow prevention and pathophysiology

Topic: No Reflow

Speaker: Doctor P. Wenzel (Mainz, DE)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Doctor Philip Wenzel

Johannes Gutenberg University Mainz (JGU), Mainz (Germany)

2 presentations

0 follower

4 more presentations in this session

The modulation of miR-129-3p levels in coronary thrombi after primary PCI discloses a novel potential mechanism underlying the no reflow phenomenon

Speaker: Doctor S. De Rosa (Catanzaro, IT)

Impaired endogenous fibrinolysis in STEMI patients undergoing PPCI is an independent predictor of recurrent cardiovascular events -the RISK PPCI study

Speaker: Doctor M. Farag (Cambridge, GB)

Multicenter randomized clinical trial of the efficacy and safety of intravenous quercetin in patients with ST-elevation acute myocardial infarction

Speaker: Doctor S. Kozhukhov (Kiev, UA)

The future of preventing reperfusion injury: achievable anytime soon?

Speaker: Doctor D. Pinto (Boston, US)

Access the full session

No-reflow prevention and pathophysiology

Speakers: Doctor P. Wenzel, Doctor S. De Rosa, Doctor M. Farag, Doctor S. Kozhukhov, Doctor D. Pinto

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

Related content

ESC Premium Access

Acute myocardial infarction with cardiogenic shock: case presentation.

29 August 2021

ESC Premium Access

Triglycerides: the underestimated player.

27 August 2021

ESC Premium Access

Inflammatory targets in atherosclerosis.

27 August 2021

ESC 365 is supported by